H

Hope Clinical Research | Canoga Park, California

Research site
(Unclaimed)
Location
22030 Sherman Way Suite 101, Canoga Park, California, United States of America
Site insights

Top conditions

Migraine Disorders (7 trials)

COVID-19 (7 trials)

Osteoarthritis (7 trials)

Non-alcoholic Fatty Liver Disease (6 trials)

Gastroparesis (5 trials)

Top treatments

Relamorelin
FX006
Tanezumab
PF-07321332
APT-1011
Rocatinlimab
Vibegron
Atogepant
Ritonavir
CTP-543

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

22 of 72
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) (ROCKET-VOYAGER)

The primary objectives of this study are to:estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-tetanus re...

Active, not recruiting
Atopic Dermatitis
Moderate-to-severe Atopic Dermatitis
Drug: Placebo
Drug: Rocatinlimab

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Placebo in 1.5ml
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placeb...

Enrolling
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Biological: ExPEC9V
Other: Placebo

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

The main aim of this study is to evaluate the efficacy of S-217622 versus placebo among outpatient adults with mild and moderate COVID-19 starting in...

Active, not recruiting
SARS-CoV-2 Infection
Drug: S-217622
Drug: Placebo

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastr...

Enrolling
Diabetic Gastroparesis
Drug: CIN-102 Dose 1
Drug: CIN-102 Dose 2

The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by th...

Active, not recruiting
Migraine
Drug: Placebo
Drug: BHV-3500 (zavegepant)

The main purpose of Part A of this study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single...

Active, not recruiting
Respiratory Syncytial Virus
Drug: mRNA-1345
Drug: Placebo

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Enrolling
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Obicetrapib

This is a two-part study designed to evaluate the effect of Estetrol (E4) 15 or 20 mg, or placebo on the severity and frequency of vasomotor symptoms...

Active, not recruiting
Menopausal Symptoms
Vasomotor Symptoms
Drug: Progesterone oral tablet
Drug: Estetrol oral tablet

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Invitation-only
Alopecia Areata
Drug: CTP-543

This is a phase 2 double-blind, randomized study of PBI-0451(Pomotrelvir) in nonhospitalized symptomatic adults with COVID-19. PBI-0451(Pomotrelvir)...

Active, not recruiting
COVID-19
Drug: PBI-0451 (Pomotrelvir)
Drug: Placebo

This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non al...

Active, not recruiting
Non-alcoholic Steatohepatitis
Drug: NNC0174 0833 10 mg/mL
Drug: NNC0194 0499 50 mg/mL

This Phase 2/3 study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP has an acceptable immunogenicity an...

Active, not recruiting
SARS-CoV-2 Infection
Drug: Intramuscular injection
Biological: Intramuscular vaccine

The purpose of VAN00010 study is to assess the safety and immunogenicity of the investigational pentavalent meningococcal ABCYW vaccine in adults and...

Enrolling
Meningococcal Infection
Healthy Volunteers
Biological: Pentavalent Meningococcal ABCYW vaccine
Biological: MenACYW conjugate vaccine

A Phase 1/ 2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokine...

Enrolling
Type 2 Diabetes Mellitus
Drug: BMF-219

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and so...

Active, not recruiting
Episodic Migraine
Drug: BOTOX
Drug: Placebo

Migraine is characterized by attacks of throbbing, moderate or severe headache, often associated with nausea, vomiting, and/or sensitivity to light a...

Enrolling
Chronic Migraine
Drug: Atogepant

The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with overactive bladder syndrome, compared to p...

Active, not recruiting
Overactive Bladder Syndrome
Drug: Placebo
Drug: V117957

This study investigates 3 different doses of orismilast modified release compared to placebo in adult patients with moderate-to-severe atopic dermati...

Active, not recruiting
Atopic Dermatitis
Skin Diseases
Drug: Placebo
Drug: Orismilast modified release tablets

Trial sponsors

Allergan logo

Allergan (9 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems